Alteogen Inc. scored another deal for its human recombinant enzyme, ALT-B4, on Nov. 8, reeling in Daiichi Sankyo Co. Ltd. in a potential $300 million deal including $20 million up front and up to $280 million in milestone payments, along with royalties based on net sales.
Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long deemed uncurable like malignant glioma.
Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long deemed uncurable like malignant glioma.
One of the current challenges of immunotherapy is the hunt for good targets, and the Claudins – a family of roughly two dozen transmembrane proteins – would appear to have a lot going for them. “Some Claudins distribute in a tissue-specific manner, and malignant transformation causes their exposition,” Cinta Hierro told the audience at the European Society of Medical Oncology (ESMO) 2024 Congress. “Others are rarely expressed in healthy tissue.”
Daiichi Sankyo Co. Ltd. has divulged compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, major depression, multiple sclerosis, multiple system atrophy, schizophrenia, autoimmune disease, Alzheimer’s disease and Parkinson’s disease, among others.
For the first time in six years, the U.K.’s National Institute for Health and Care Excellence (NICE) is refusing to recommend a breast cancer treatment. It cited price as the issue.
An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with programmed cell death 1 ligand 1 (PD-L1) blockade as a novel strategy to enhance antitumor immunity against tumors with low antigenicity.
Daiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment of narcolepsy.
Partners Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. received a complete response letter (CRL) from the U.S. FDA for their first-in-class HER3-directed antibody-drug conjugate HER3-DXd (patritumab deruxtecan) to treat patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer.
Partners Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. received a complete response letter (CRL) from the U.S. FDA for their first-in-class HER3-directed antibody-drug conjugate HER3-DXd (patritumab deruxtecan) to treat patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer.
